Joseph Larosa - Dec 8, 2023 Form 4 Insider Report for REGENERON PHARMACEUTICALS, INC. (REGN)

Role
EVP General Counsel and Secret
Signature
/s/**Joseph LaRosa
Stock symbol
REGN
Transactions as of
Dec 8, 2023
Transactions value $
-$1,283,605
Form type
4
Date filed
12/12/2023, 04:01 PM
Previous filing
Mar 27, 2023
Next filing
Jan 4, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction REGN Common Stock Tax liability -$719K -852 -2.9% $843.79 28.6K Dec 8, 2023 Direct
transaction REGN Common Stock Award $0 +2.13K +7.47% $0.00 30.7K Dec 8, 2023 Direct F1
transaction REGN Common Stock Tax liability -$565K -669 -2.18% $844.09 30K Dec 11, 2023 Direct
holding REGN Common Stock 3.37K Dec 8, 2023 2022 GRAT
holding REGN Common Stock 355 Dec 8, 2023 By 401(k) Plan

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction REGN Non-Qualified Stock Option (right to buy) Award $0 +7.65K $0.00 7.65K Dec 8, 2023 Common Stock 7.65K $843.79 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Award of Restricted Stock under the Second Amended and Restated 2014 Long-Term Incentive Plan that vests 50% on December 8, 2025 and 50% on December 8, 2027.
F2 The stock option award vests in four equal annual installments, commencing one year after the date of grant.